tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

60 Degrees Pharmaceuticals Inc

SXTP
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
1.500USD
-0.070-4.46%
์ข…๊ฐ€ย 07-27 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
3.96M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
TradingKey ์ฐจํŠธ
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

-4.46%

5์ผ

-0.66%

1๊ฐœ์›”

-6.83%

6๊ฐœ์›”

-68.88%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

-26.22%

1๋…„

+14.50%

ํ•ต์‹ฌ ์ˆ˜์น˜
1.520์‹œ๊ฐ€
1.630์ตœ๊ณ ๊ฐ€
1.69K๊ฑฐ๋ž˜๋Ÿ‰
์†์‹คP/E TTM
์†์‹ค๋™์  P/E ๋น„์œจ
--๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.06%ํšŒ์ „์œจ
1.570์ „์ผ ์ข…๊ฐ€
1.510์ตœ์ €๊ฐ€
1.18K๋งค์ถœ์•ก
์†์‹ค์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
-0.83P/B
0.00%๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
-119.00%ROA
14.68052์ฃผ ์ตœ๊ณ ๊ฐ€
-0.23๊ฑฐ๋ž˜๋Ÿ‰ ๋น„์œจ
-8.43M์ˆœ์ด์ต
2.64M์ฃผ์‹
-6.8035์ฃผ๋‹น์ˆœ์ด์ต
--๋ฒ ํƒ€
--ROE
1.29052์ฃผ ์ตœ์ €๊ฐ€
7.64%๋ณ€๋™ ํญ
47.12%์ด ์ด์ต๋ฅ 
3.96M์‹œ๊ฐ€์ด์•ก
-0.35๋ณด์ƒ/์œ„ํ—˜
7.17%์œ„ํ—˜๋ฅ 

TradingKey 60 Degrees Pharmaceuticals Inc ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2026-07-27

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

60 Degrees Pharmaceuticals Inc์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ๊ฑด์ „ํ•œ ์ƒํƒœ์ด๋ฉฐ, ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ์ƒ๋‹นํ•ฉ๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—…์—์„œ 155๊ฐœ ์ค‘ 97์œ„ ๋žญํ‚น.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ง€๋‚œ ํ•œ ๋‹ฌ ๋™์•ˆ ์—ฌ๋Ÿฌ ์• ๋„๋ฆฌ์ŠคํŠธ๊ฐ€ ํ•ด๋‹น ๊ธฐ์—…์„ ๋งค์ˆ˜(์œผ)๋กœ ํ‰๊ฐ€ํ–ˆ์œผ๋ฉฐ, ์ตœ๊ณ  ๋ชฉํ‘œ ๊ฐ€๊ฒฉ์€ 3.70์ž…๋‹ˆ๋‹ค.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ์•ˆ์ •์ ์ธ ์ƒํƒœ๋ฅผ ์œ ์ง€ํ•  ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ๋ถ€์ง„ํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘์—ˆ์ง€๋งŒ, ๊ธฐ์—…์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ํƒ„ํƒ„ํ•ฉ๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

60 Degrees Pharmaceuticals Inc ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
97 / 155
์ „์ฒด ์ˆœ์œ„
231 / 4282
์‚ฐ์—…
์ œ์•ฝ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ฏธ๋””์–ด ๋ณด๋„

์ตœ๊ทผ 24 ์‹œ๊ฐ„
๋ณด๋„ ์ˆ˜์ค€

๋งค์šฐ ๋‚ฎ์€
๋งค์šฐ ๋†’์€
๊ธ์ •

60 Degrees Pharmaceuticals Inc ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Companyโ€™s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
๋†’์€ ์„ฑ์žฅ
ํšŒ์‚ฌ์˜ ๋งค์ถœ์€ ์ง€๋‚œ 3๋…„๊ฐ„ ๊พธ์ค€ํžˆ ์„ฑ์žฅํ•ด์™”์œผ๋ฉฐ, ์—ฐํ‰๊ท  455.70%์˜ ์ฆ๊ฐ€์œจ์„ ๊ธฐ๋กํ–ˆ์Šต๋‹ˆ๋‹ค.
์„ฑ์žฅ ์ค‘
ํšŒ์‚ฌ๋Š” ์„ฑ์žฅ ๋‹จ๊ณ„์— ์žˆ์œผ๋ฉฐ, ์ตœ์‹  ์—ฐ๊ฐ„ ์ˆ˜์ต์€ ๋ฏธํ™” 1.41M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณ ์ˆ˜์ต ์„ฑ์žฅ
ํšŒ์‚ฌ์˜ ์ˆœ์ด์ต์€ ์—…๊ณ„ ์„ ๋‘๋ฅผ ๋‹ฌ๋ฆฌ๊ณ  ์žˆ์œผ๋ฉฐ, ์ตœ๊ทผ ์—ฐ๊ฐ„ ์ˆœ์ด์ต์€ ๋ฏธํ™” 1.41M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณต์ •ํ•œ ๊ฐ€์น˜
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ -0.23๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ์ค‘๊ฐ„ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค์ˆ˜
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 228.38K์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 38.27% ์ฆ๊ฐ€ํ–ˆ์Šต๋‹ˆ๋‹ค.

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

2 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
3.700
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+150.00%
์ƒ์Šน ์—ฌ๋ ฅ

60 Degrees Pharmaceuticals Inc ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์˜ˆ์ƒ๎˜

์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€

2 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
3.700
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+150.00%
์ƒ์Šน ์—ฌ๋ ฅ
๊ฐ•๋ ฅ ๋งค์ˆ˜
๋งค์ˆ˜
์œ ์ง€
๋งค๋„
๊ฐ•๋ ฅ ๋งค๋„

๋™์ข…์—…๊ณ„ ๋น„๊ต

160
์ด๊ณ„
6
์ค‘๊ฐ„
9
ํ‰๊ท 
ํšŒ์‚ฌ ์ด๋ฆ„
ํ‰๊ฐ€
๋ถ„์„๊ฐ€
60 Degrees Pharmaceuticals Inc
SXTP
2
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32

์ง€ํ‘œ๎˜

์ง€ํ‘œ
๋งค๋„(2)
์ค‘๋ฆฝ(1)
๋งค์ˆ˜(4)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MACD(12,26,9)
-0.010
๋งค๋„
RSI(14)
51.392
์ค‘๋ฆฝ
STOCH(KDJ)(9,3,3)
54.482
๋งค์ˆ˜
ATR(14)
0.115
์ €๋ณ€๋™์„ฑ
CCI(14)
107.986
๋งค์ˆ˜
Williams %R
28.571
๋งค์ˆ˜
TRIX(12,20)
-0.186
๋งค๋„
StochRSI(14)
100.000
๋งค์ˆ˜
์ด๋™ ํ‰๊ท 
๋งค๋„(6)
์ค‘๋ฆฝ(0)
๋งค์ˆ˜(0)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MA5
1.532
๋งค๋„
MA10
1.521
๋งค๋„
MA20
1.581
๋งค๋„
MA50
1.528
๋งค๋„
MA100
1.681
๋งค๋„
MA200
2.842
๋งค๋„

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

60 Degrees Pharmaceuticals Inc ์ •๋ณด๎˜

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Companyโ€™s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
์ข…๋ชฉ ์ฝ”๋“œ SXTP
ํšŒ์‚ฌ60 Degrees Pharmaceuticals Inc
CEODow (Geoffrey S)
์›น์‚ฌ์ดํŠธhttps://60degreespharma.com/

์ฃผ์ฃผ๎˜

์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Kathmere Capital Management
5.49%
Orca Capital GmbH
1.58%
UBS Financial Services, Inc.
1.19%
Dow (Geoffrey S)
0.64%
Knight Therapeutics, Inc.
0.32%
๊ธฐํƒ€
90.79%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

60 Degrees Pharmaceuticals Inc(SXTP)์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
60 Degrees Pharmaceuticals Inc(SXTP)์˜ ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 1.58์ž…๋‹ˆ๋‹ค.

60 Degrees Pharmaceuticals Inc์˜ ์ข…๋ชฉ ๊ธฐํ˜ธ(Symbol)๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
60 Degrees Pharmaceuticals Inc์˜ ์ข…๋ชฉ ์ฝ”๋“œ๋Š” SXTP์ž…๋‹ˆ๋‹ค.

60 Degrees Pharmaceuticals Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
60 Degrees Pharmaceuticals Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” 14.68์ž…๋‹ˆ๋‹ค.

60 Degrees Pharmaceuticals Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
60 Degrees Pharmaceuticals Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” 1.29์ž…๋‹ˆ๋‹ค.

60 Degrees Pharmaceuticals Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
60 Degrees Pharmaceuticals Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ 4.17M์ž…๋‹ˆ๋‹ค.

60 Degrees Pharmaceuticals Inc(SXTP)์˜ ํ˜„์žฌ ํˆฌ์ž ๋“ฑ๊ธ‰์€ ๋งค์ˆ˜, ๋ณด์œ , ๋งค๋„ ์ค‘ ์–ด๋–ค๊ฐ€์š”?

๎™Œ
์• ๋„๋ฆฌ์ŠคํŠธ๋“ค์— ๋”ฐ๋ฅด๋ฉด, 60 Degrees Pharmaceuticals Inc(SXTP)๋Š” ์ „๋ฐ˜์ ์ธ ํ‰๊ฐ€์—์„œ ๊ตฌ์ž…ํ•˜๋‹ค ๋“ฑ๊ธ‰์„ ๋ฐ›๊ณ  ์žˆ์œผ๋ฉฐ, ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” 3.70์ž…๋‹ˆ๋‹ค.

60 Degrees Pharmaceuticals Inc(SXTP)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
60 Degrees Pharmaceuticals Inc(SXTP)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ -11.74์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ